Bacil Pharma Ltd — Important, 14-10-2025: Company Update

Bacil Pharma confirmed its adherence to dematerialization procedures for the quarter ending September 30, 2025. The company’s Registrar and Transfer Agent verified that dematerialization requests were processed and registered with depositories within the required timeframe. The total shares outstanding increased to 14,353,000 from 5,890,000 last quarter, with principal listing approval received for these shares. The shareholding structure includes 3,547,820 NSDL demat shares, 8,703,180 CDSL demat shares, and 2,102,000 physical shares. This demonstrates robust operational compliance and efficient investor services, with all investor complaints for the period also successfully resolved.